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E2F regulation is essential for normal cell cycle pro-
gression. Therefore, it is not surprising that squamous
cell carcinoma cell lines (SCC) overexpress E2F1 and
exhibit deregulated E2F activity when compared with
normal keratinocytes. Indeed, deliberate E2F1 deregu-
lation has been shown to induce hyperplasia and skin
tumor formation. In this study, we report on a dual role
for E2F as a mediator of keratinocyte proliferation and
modulator of squamous differentiation. Overexpression
of E2F isoforms in confluent primary keratinocyte cul-
tures resulted in suppression of differentiation-associ-
ated markers. Moreover, we found that the DNA binding
domain and the trans-activation domain of E2F1 are
important in mediating suppression of differentiation.
Use of a dominant/negative form of E2F1 (E2F d/n) found
that E2F inhibition alone is sufficient to suppress the
activity of proliferation-associated markers but is not
capable of inducing differentiation markers. However, if
the E2F d/n is expressed in differentiated keratinocytes,
differentiation marker activity is further induced, sug-
gesting that E2F may act as a modulator of squamous
differentiation. We therefore examined the effects of
E2F d/n in a differentiation-insensitive SCC cell line. We
found that treatment with the differentiating agent, 12-
O-tetradecanoyl-phorbol-13-acetate (TPA), or expres-
sion of E2F d/n alone had no effect on differentiation
markers. However, a combination of E2F d/n  TPA
induced the expression of differentiation markers. Com-
bined, these data indicate that E2F may play a key role
in keratinocyte differentiation. These data also illus-
trate the unique potential of anti-E2F therapies in ar-
resting proliferation and inducing differentiation of
SCCs.
The major function of the skin is to act as a barrier between
the internal and external environment. The skin is divided into
two layers, the dermis and the epidermis, of which the major
cell type in the epidermis is the keratinocyte. During the
strictly regulated process of differentiation, keratinocytes un-
dergo morphological and biochemical changes, resulting in
dead, enucleated, flat cells that are eventually sloughed from
the skin surface. This process of differentiation is initiated by
the irreversible growth arrest and suppression of proliferation-
specific genes such as p53 (1), E2F1 (2, 3), cdk1 (4), and keratin
14 (5) in proliferative basal cells. Concomitant with the sup-
pression of proliferation-specific genes, there is a corresponding
induction of differentiation-specific genes, such as keratin 10
(6), cornifin (7), and transglutaminase type 1 (2). This process
of growth suppression and induction of terminal differentiation
is predominantly regulated at the transcriptional level by sev-
eral transcription factor families such as AP1, Sp1, AP2, and
E2F (8–10) and disruption of this process frequently accompa-
nies the onset of neoplasia.
E2F was first identified as a nuclear factor capable of binding
to the adenovirus E2 promoter (11). To date, six members of the
E2F transcription factor family have been cloned, E2Fs 1–6
(12–24). E2F exists as a heterodimeric complex in association
with a dimeric partner protein, DP1 or DP2 (25–27). This “free”
E2F complex acts as a potent trans-activator of E2F-responsive
genes. However, the activity of E2F is subject to regulation
through inhibitory interactions with hypophosphorylated
forms of the pocket proteins, pRb, p107, and p130 (13–18, 21,
28). Specifically, E2Fs 1–3 preferentially bind to pRb, while
E2Fs 4–5 bind p107 and E2F5 binds p130. This direct associ-
ation of E2F isoforms with their cognate pocket protein partner
acts to repress E2F-mediated transcriptional activity. In some
instances, this repression requires further interactions with
specific histone deacetylases (29, 30). The presence of these
various E2F-pocket protein complexes act to regulate passage
through various phases of the cell cycle. In particular, certain
complexes are associated with a specific phase of the cell cycle:
the E2F5p130 complex associates with G0 (31), E2F1–3pRb
with G1 (32) and E2F4p107 with G0/G1 phase (18). Thus, the
coordinated activation/inactivation of these complexes illus-
trate that cell cycle progression is controlled by complex tran-
scriptional means. Despite clear evidence implicating E2F in-
volvement in cell cycle regulation, there is also compelling
evidence for other roles of E2F. For instance, E2Fs 1–3 have
been implicated in the initiation of apoptosis (33–36). More
recently, E2Fs have also been demonstrated to play a role in
the regulation of myocyte, megakaryocyte, and adipocyte dif-
ferentiation (37–39).
We have previously reported that the induction of keratino-
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cyte growth arrest, in response to growth inhibitors, is associ-
ated with decreased E2F1 mRNA expression (2, 3) and de-
creased E2F DNA binding activity (3). In contrast, squamous
cell carcinoma (SCC)1 cell lines showed no alterations in E2F
DNA binding activity nor E2F1 mRNA expression in response
to these same growth inhibitors (3). Given the role of E2F in
proliferation, we proposed that the deregulation of E2F activity
may contribute causally to the deregulated growth observed in
SCC cell lines (3). Indeed, several lines of evidence support this
contention. For example, deliberate deregulation of E2F activ-
ity in vitro using HPV 16 E7 protein resulted in growth inhib-
itor-insensitivity in normal keratinocytes (3). These data are
further strengthened by more recent reports that E2F1 mRNA
overexpression occurs in primary SCCs compared with normal
epidermis (10). Furthermore, deliberate deregulation of E2F1
expression in the skin of transgenic mice induces hyperplasia
and cooperates with ras in skin tumor development (40). Com-
bined, these data suggested that the deregulation of E2F1
could contribute to skin cancer formation. While the overex-
pression and activation of E2F in human SCCs may contribute
to their deregulated proliferation, we became interested in
whether this overexpression would have other implications on
the squamous differentiation program. To this end, we found
some evidence that E2F1 may have a dual role as both a
mediator of keratinocyte proliferation and a suppressor of
squamous differentiation (10). If this were true, it would sug-
gest that deregulated E2F in SCCs may serve to deregulate
proliferation and repress terminal differentiation. Therefore, in
the present study, we examined the possibility that E2F may
act as a biologically relevant modulator of squamous differen-
tiation and that E2F inhibition may provide the basis of a
“differentiation therapy” for SCCs.
EXPERIMENTAL PROCEDURES
Cell Culture—Human epidermal keratinocytes (HEKs) were isolated
and cultured from neonatal foreskins as described (3). The SCC cell line,
KJD-1/SV40, were grown in culture as previously reported (10). Growth
arrest and differentiation was induced by maintaining confluent cells in
culture over 48 h or by treatment with the protein kinase C (PKC)
activator, 12-O-tetradecanoyl-phorbol-13-acetate (TPA, 50 ng/ml for
16–48 h). Both these treatment regimes induce robust and reproducible
differentiation in HEKs but not in SCC cell lines (10, 41–43).
Transfection of Cells and Reporter Assays—The human cdc2 pro-
moter construct driving expression of a CAT reporter gene (cdc2-CAT)
has been previously described (4). The 2.9-kb transglutaminase type 1
promoter linked to a firefly luciferase gene (TG-1 Luc), keratin 10
reporter (K10-Luc), -actin-CAT reporter gene and -actin-luciferase
reporter gene have also been previously described (4, 6, 10, 41, 45).
-actin-CAT or -actin-Luc reporters were used to normalize for trans-
fection efficiency. The CMV-E2F1 construct was a kind gift from Dr.
Kristian Helin (15). The CMV-E2F 2–5 constructs were generous gifts
from Dr. David Livingstone (46). The mutant E2F1 constructs,
132E2F1 and 409E2F1, were kindly provided by Dr. Joseph Nevins
(47). The E2F1 dominant-negative (E2Fd/n) construct codes for amino
acids 116–235, spanning for the DNA binding domain and heterodimer-
ization domain (10).
Transient transfections of cells were performed in a 10-cm2 well,
when cells were either 50 or 100% confluent. Reporter activity was
assayed 48 h post-transfection. Transfection protocols for cultured
HEKs using LipofectAMINE (Invitrogen, Australia) and KJD-1/SV40
cells using Effectene (Qiagen) have been described previously (10).
Transfections were performed in triplicate and repeated at least three
times.
Chloramphenicol acetyltransferase assays (CAT) were performed us-
ing a CAT ELISA kit (Roche Applied Science) as per manufacturer’s
instructions. The luciferase assay protocol has been previously reported
(4, 41).
Protein Isolation and Western Blotting—Protein isolation and West-
ern blotting protocols have been previously described (48). All antibod-
ies were purchased from Santa Cruz Biotechnologies. Dilutions of rab-
bit polyclonal antibodies were as follows: E2F1 (sc-193) 1:200, E2F2
(sc-632) 1:1000, E2F3 (sc-878) 1:200, E2F4 (sc-866) 1:1000, and E2F5
(sc-999) 1:1000. All immunodetection was visualized after reaction with
1:3000 horseradish peroxidase-conjugated goat anti-rabbit and incuba-
tion with ECL reagent (48).
RNA Isolation and Detection by RT-PCR—KJD-1/SV40 cells were
transfected as described above, but with the addition of a green fluo-
rescent protein (GFP) expression plasmid (1:3, GFP:E2Fd/n). Forty-
eight hours post-transfection, cells were harvested and the GFP-posi-
tive cells enriched by fluorescent analysis cell sorting (FACS; Ref. 49).
Total RNA isolation and reverse transcriptase-polymerase chain reac-
tion (RT-PCR) have been described (49, 50). Oligonucleotides for esti-
mating the expression of TG-1 are as follows: 5-TG-1 GCCGAGAGC-
ACCACACAGACG, 3-TG-1 CGTAGTAAATTCTCCCAGACTC; 5-actin
GAAATCGTGCGTGACATTAAG, 3-actin CTAGAAGCATTTGCGGT-
GGACGATGGAGGG GCC. All amplifications were performed under
linear conditions with respect to cycle number (50).
RESULTS
E2Fs 1–5 Can Suppress the Activity of Differentiation-specific
Markers in Normal Human Keratinocytes—In order to deter-
mine whether the overexpression of E2F1 observed in SCCs
(10) could affect the ability of the cells to undergo squamous
differentiation, we examined the effects of E2F overexpression
in normal keratinocytes.
Keratinocyte differentiation is characterized by irreversible
growth arrest, the suppression of proliferation-specific markers
(3, 51) and the induction of differentiation-specific markers
(e.g. TG-1 Luc or K10-Luc). The implications of E2F1 overex-
pression in normal keratinocytes were therefore examined by
measuring differentiation-specific marker activity in cells in-
duced to differentiate by two independent pathways (conflu-
ence or PKC activation, Refs. 41, 52, and 53). Our data dem-
onstrate that cultured HEKs have increased TG-1 Luc and
K10-Luc activity when induced to differentiate either by prior
treatment of cells with TPA or by growth to confluence for 48 h
(Fig. 1). Transfection of E2F1 into these differentiated cells was
accompanied by significant reduction in activity of these differ-
entiation-specific markers. This observation indicates that
E2F1 can suppress differentiation-specific reporters in kerati-
nocytes induced to differentiate by two different stimuli.
In addition, co-transfection of E2Fs 1–5 and the TG-1 Luc
reporter into differentiated keratinocytes showed that E2Fs
1–5 were all able to significantly suppress TG-1 Luc activity in
confluent/differentiated HEKs (Fig. 2). This indicates that the
ability to suppress differentiation markers is shared by E2Fs
1–5. Since E2Fs 4–5 do not contain a cyclin binding domain
(18, 21) and are unable to induce apoptosis (33–36, 54–57),
these data also suggest that the phenomenon observed is cell
cycle phase-independent, cyclin binding domain-independent,
and apoptosis-independent.
The DNA Binding Domain and trans-Activation Domain of
E2F1 Is Essential for Suppression of Differentiation-specific
Marker Activity—To examine the domain requirement of E2F1
to suppress squamous differentiation, we employed two E2F1
mutants (Fig. 3). The 132E2F1 mutant contains a point mu-
tation in the DNA binding domain, which abolishes its activity
(47). Similarly, the 409E2F1 mutant possesses a frameshift
mutation that eliminates both the trans-activation domain and
pocket protein binding domain of E2F1 (47). Both the DNA
binding domain mutant (132E2F1) and trans-activation do-
main mutant (409E2F1) are unable to induce the prolifera-
tion-specific and E2F-responsive cdc2-CAT reporter (Fig. 3A).
Furthermore, by measuring TG-1 promoter activity, we show
that both mutants are unable to suppress TG-1 Luc activity in
1 The abbreviations used are: SCC, squamous cell carcinoma cell
lines; HEK, human epidermal keratinocytes; CAT, chloramphenicol
acetyltransferase; GFP, green fluorescent protein; TPA, 12-O-tetra-
decanoyl-phorbol-13-acetate; ELISA, enzyme-linked immunosorbent
assay.
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differentiated keratinocytes (Fig. 3B). These data demonstrate
that both the DNA binding domain of E2F1 and the trans-
activation domain of E2F1 are important for the suppression of
differentiation-specific markers in HEKs. These data also sug-
gest that suppression of differentiation is unlikely to be medi-
ated by “squelching.” It is interesting to note that E2Fd/n was
able to superinduce/derepress TG-1 Luc activity to levels above
that of differentiated HEKs. Thus, E2F1 overexpression sup-
presses TG-1 Luc and E2F inhibition induces TG-1 Luc. These
data are consistent with a role for E2F as a modulator of
squamous differentiation.
E2F Is Required For but Not Sufficient to Induce Squamous
Differentiation—Given that the E2Fd/n could further induce
TG-1 Luc activity in confluent cells, we examined the possibil-
ity that in proliferative cells the induction of differentiation
was actively suppressed by E2F. If this were true, then inhibi-
tion of E2F in proliferative cells should suppress proliferation
markers and induce differentiation markers. Indeed, inhibition
of E2F causes suppression of the proliferation-specific marker
activity, cdc2-CAT (Fig. 4A). However, inhibition of E2F is not
sufficient to induce TG-1 Luc activity (Fig. 4B). Paradoxically,
inhibition of E2F in confluent/differentiated HEKs superinduc-
es/derepresses both TG-1 Luc and K10-Luc activity (Fig. 4C).
These data indicate that (i) E2F suppression is not sufficient to
induce differentiation, (ii) E2F inhibits the initiation of squa-
mous differentiation (Fig. 1), and (iii) E2F inhibition is able to
derepress/superinduce differentiation markers in differenti-
ated HEKs. For these reasons, we believe E2F may be acting as
a modulator of the differentiation phenotype.
If E2F were to act as a modulator of squamous differentia-
tion in keratinocytes, it would be of interest to determine which
E2F isoforms are expressed in differentiated keratinocytes and
hence which isoforms potentially contribute to the suppression.
Whole cell extracts were blotted and probed with E2F 1–5
antibodies. Both proliferating and confluent HEKs were found
to express E2Fs 1–5 protein (Fig. 5). These data indicate that
any one of the E2F isoforms could have the potential to mod-
ulate squamous differentiation. E2F5 was the only isoform
whose expression was increased while E2F2 was the only iso-
form whose expression was decreased in differentiated cells.
Inhibition of E2F in the Presence of a Differentiation-induc-
ing Agent Reinstates Differentiation in a Squamous Cell Car-
cinoma Cell Line—If E2F acts as a modulator of differentiation,
this may explain the differentiation-resistance observed in can-
cer cells in which E2F is overexpressed. The KJD-1/SV40 cells
represent a SCC cell line that was produced by transforming
normal keratinocytes with the SV40 virus. These cells were
used in transfection studies in order to determine whether the
inhibition of E2F was able to reinstate TG-1 Luc activity. When
FIG. 1. E2F1 suppresses differentiation markers in primary
human keratinocyte cultures. Human epidermal keratinocytes were
transfected with a luciferase reporter linked to the transglutaminase-1
promoter (TG-1 Luc) (A) or keratin-10 promoter (K10 Luc) (B). Each
construct was co-transfected with a -actin-CAT reporter, to correct for
transfection efficiency, as well as either an E2F1 expression plasmid or
GFP expression plasmid. Cells were transfected when proliferating
(Prol) or differentiated (Conf, TPA). Cells were induced to differentiate
by growth to confluence or treatment of cells with medium supple-
mented with 50 ng/ml of TPA for 16 h prior to transfection. Data
presented as mean  S.E. of triplicate determinations of at least three
experiments (*, p  0.05 compared with Prol).
FIG. 2. E2Fs 1–5 suppress TG-1 Luc in confluent cultures of
primary keratinocytes. Confluent cultures of human epidermal ke-
ratinocytes were transfected with a luciferase reporter linked to the
transglutaminase-1 promoter (TG-1 Luc). Each construct was co-trans-
fected with a -actin-CAT reporter, to correct for transfection efficiency,
as well as E2F expression plasmids (E2F1, E2F2, E2F3, E2F4, or E2F5)
or GFP as control. Data presented as mean  S.E. of triplicate deter-
minations of at least three experiments and are normalized such that
the value of the control is 100 (*, p  0.05 compared with control). CBD,
cyclin binding domain; DBD, DNA binding domain; HDD, heterodimer-
ization domain; TD, trans-activation domain, and PPBD, pocket protein
binding domain.
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proliferating KJD-1/SV40 cells were transfected with E2Fd/n,
TG-1 Luc activity was not altered (Fig. 6A). In contrast, our
earlier studies had shown that expression of E2Fd/n in KJD-
1/SV40 cells could inhibit the proliferation-specific marker,
cdc2-CAT (10). When proliferating KJD-1/SV40 cells were
treated with TPA, there was also no induction of TG-1 Luc
activity. However, treatment of KJD-1/SV40 cells with both a
differentiation-inducing agent (TPA), and E2Fd/n resulted in a
significant increase in TG-1 Luc activity (Fig. 6A). To demon-
strate that the reinstatement of differentiation-specific activi-
ties were not restricted to our reporter-based assay, we re-
peated the experiment using the induction of TG-1 mRNA as
marker of differentiation (Fig. 6B). Using this independent
strategy we were able to confirm that a combination of TPA and
E2Fd/n was able to induce differentiation markers in the pre-
viously differentiation-resistant KJD-1/SV40 cell line.
DISCUSSION
This study presents evidence implicating the E2F family as
potent and biologically relevant modulators of squamous dif-
ferentiation. This extends the known functions of E2F as key
regulators of proliferation (58, 59) and apoptosis (58, 60, 61) to
include regulation of keratinocyte terminal differentiation.
Such a role may have significant implications to our under-
standing of squamous neoplasia and to the development of
differentiation therapies for SCC. A role for the E2F family as
differentiation modulators is based on the following observa-
tions: (i) E2F1 suppresses differentiation-specific markers re-
gardless of stimuli used to induce squamous differentiation, (ii)
the ability to suppress squamous differentiation is shared by
E2Fs 1–5, (iii) inhibition of E2F is not sufficient to induce
keratinocyte differentiation but can superinduce/derepress dif-
ferentiation markers in differentiated cells, (iv) the superin-
duction/derepression mediated by E2Fd/n was observed for
both TG-1 Luc and K10-Luc activity, (v) E2F isoforms are
FIG. 3. E2F1 suppression of TG-1 Luc requires the DNA bind-
ing domain, trans-activation domain and pocket protein bind-
ing domain. A, proliferating (Prol) and B, differentiated (Conf) kera-
tinocytes were transfected with a reporter linked to either the (A) cdc2
promoter (cdc2-CAT) or (B) transglutaminase-1 promoter (TG-1 Luc).
Each plasmid was co-transfected with a -actin-CAT or -actin-Luc
reporter, to normalize for transfection efficiency, as well as an expres-
sion plasmid for one of the following: E2Fd/n, E2F1, 132E2F1, 409
E2F1, or GFP as control. Data presented as mean  S.E. of triplicate
determinations of at least three experiments (*, p 0.05 compared with
prol (A) or conf (B)). CBD, cyclin binding domain; DBD, DNA binding
domain; HDD, heterodimerization domain; TD, trans-activation do-
main; and PPBD, pocket protein binding domain.
FIG. 4. E2F may modulate squamous differentiation. A and B,
proliferating and C, differentiated keratinocytes were transfected with
a reporter linked to the cdc2 promoter (cdc2-CAT) (A), transglutami-
nase-1 promoter (TG-1 Luc) (B), or keratin 10 promoter (K10-Luc) (C).
Each condition was transfected with a -actin-CAT or -actin-Luc re-
porter, to normalize for transfection efficiency, as well as E2Fd/n or
pCDNA-GFP as control. Data presented as mean  S.E. of triplicate
determinations of at least three experiments (*, p 0.05 compared with
control).
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expressed in both proliferating and differentiated keratino-
cytes, (vi) differentiation-insensitive SCCs overexpress E2F1
(10, 43), and (vii) E2F inhibition makes SCC cell lines permis-
sive to differentiation stimuli. Together, these data lend sup-
port to the notion that E2F possesses biological properties
expected of a modulator of squamous differentiation.
Our data indicate that E2F may play a dual role in promot-
ing keratinocyte proliferation and modulating squamous differ-
entiation. In this capacity, E2F members would participate in
proliferation control of undifferentiated keratinocytes and
would actively prevent them from undergoing differentiation.
However, once a cell receives a signal to withdraw from the cell
cycle and commits to differentiation (associated with loss of
proliferation-competence), E2Fs would assume an active role
as negative modulators of differentiation. In this model, E2Fs
would be predicted to regulate the extent of the differentiation
response and in concert with other differentiation-specific ac-
tivators/repressors, the level of differentiation. In this way, the
function of E2F may be considered analogous to the inhibitory
function of the cyclin-dependent kinase inhibitor, p21Cip1/WAF1,
in regulating primary mouse keratinocyte differentiation (62).
However, studies with p21 suggest that it is actively involved
in repression of differentiation. In contrast, our data indicate
that E2F inhibition is required for the initiation of differenti-
ation but is not sufficient to initiate differentiation. Of interest
is the observation that E2Fs, in the present study, and p21, in
an earlier report (62), mediate their effects via a cell cycle-
independent process. In addition, our data with the E2Fd/n
suggests that the process of differentiation is not a direct result
of growth arrest but an independent process arising after the
cessation of proliferation. If differentiation was a result of
growth arrest, inhibition of E2F should suffice to cause both
growth arrest and entry into terminal differentiation. How-
ever, our results demonstrate that although E2F inhibition was
sufficient to suppress the activity of proliferation-specific
markers, it was not able to induce differentiation-specific
marker activity. This indicates that terminal differentiation is
not merely a result of growth arrest, but that differentiation is
initiated and modulated by mechanisms yet to be understood
that lie downstream of growth arrest and require an independ-
ent stimulus (Fig. 7). This observation is strengthened by pre-
vious reports that growth arrest of epidermal keratinocytes is
not sufficient to induce differentiation (2, 4, 49).
A role for E2F in differentiation is not entirely unprece-
dented since E2Fs are known to modify myocyte, megakaryo-
cyte, and adipocyte differentiation (37–39). In myocytes and
megakaryocytes, E2F1 suppression is required in order for
differentiation initiation to occur (37, 38). This situation is
similar to keratinocytes although studies with myocytes and
megakaryocytes did not extend to examining effects in differ-
entiated cells (37, 38). More recently, it was reported that E2F1
and E2F4 act antagonistically in regulating terminal adipocyte
differentiation (39). In this model, E2F plays an active role in
adipogenesis in which E2F1 predominates in proliferating adi-
pocytes and serves to initiate differentiation (39). Subse-
quently, E2F4 is activated and displaces E2F1, thereby inhib-
iting E2F1 activity (39). Thus, the mechanism by which E2F
controls adipocyte differentiation is through E2F1 promoting
differentiation whereas in keratinocytes, we propose that E2Fs
1–5 suppress the initiation of differentiation. Data from the
adipocyte study compared with results from the present study
suggest that the role of E2F in differentiation may be cell
type-specific, tissue-specific, and transformation-specific. This
latter point would also explain why an earlier report with the
HaCaT cell line (63) differs to that of primary keratinocyte
FIG. 5. E2Fs 1–5 are expressed in primary human keratino-
cytes. Proliferative (P) and differentiated (D) keratinocytes were har-
vested, total cellular protein isolated, and 5 g of protein subjected to
Western blot analysis for the expression of E2Fs 1–5.
FIG. 6. E2F inhibition makes KJD-1/SV40 cells permissive to
TPA-mediated differentiation. Proliferating KJD-1/SV40 cells were
transfected with a luciferase reporter linked to the transglutaminase-1
promoter (TG-1 Luc). Cells were co-transfected with -actin-CAT re-
porter (A), to adjust for transfection efficiency, GFP (B), and either the
E2Fd/n plasmid or pCDNA-GFP control (pCDNA). After transfection,
cells remained in growth media or were treated with 50 ng/ml of TPA
for 48 h. A, data are presented as mean  S.E. of triplicate determina-
tions of at least three experiments and normalized such that the value
of the control is 100 (*, p  0.05 compared with control). B, transfected
cells (GFP-positive) were selected for by FACS. mRNA levels for actin or
TG-1 were then estimated in the transfected cells by RT-PCR.
FIG. 7. Model illustrating the requirement for independent
stimuli to induce growth inhibition or differentiation in
keratinocytes.
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cultures. HaCaT cells are an immortalized keratinocyte cell
line known to lack p53 (64), undergo spontaneous transforma-
tions (65), demonstrate mixed responses to differentiation
stimuli (43) and exhibit different patterns of E2F isoform ex-
pression when compared with human primary keratinocytes
(43).
The mechanism by which E2F suppresses differentiation-
specific markers is unknown. However, our data allow us to
exclude a number of mechanisms. Our data clearly indicate
that E2Fs 1–5 suppress the activity of differentiation-specific
markers. Since E2Fs 1–3 can induce apoptosis and E2F4 can-
not (33–36, 54–57), it is unlikely that the loss of differentiation-
specific marker activity is due to E2F-induced death of the cell.
Moreover, since E2F4 and E2F5 suppress squamous differen-
tiation, yet lack a cyclin binding domain, we can conclude that
E2F suppresses squamous differentiation through a cyclin
binding domain-independent pathway. Similarly, we can ex-
clude the nuclear export sequence of E2F 4 and 5 since E2Fs
1–3 lack this sequence (66, 67) yet are still able to suppress
differentiation. While it could be argued that E2F overexpres-
sion may cause a squelching phenomenon, and hence suppres-
sion of differentiation-specific markers, this would also seem
unlikely. For instance, single mutations within different do-
mains of E2F1 (132 and 409) render them unable to sup-
press differentiation markers thereby arguing against a
squelching phenomenon. In contrast to the above findings, our
data consistently indicate that the trans-activation domain,
pocket protein binding domain and DNA binding domain of
E2Fs are critical for suppressing squamous differentiation.
Similarly, the antagonistic effects of E2Fd/n, which lacks the
pocket protein binding domain and trans-activation domain,
would suggest that these domains are central to the ability of
E2F to suppress differentiation. This critical need for the trans-
activation domain implies that the recruitment of other cofac-
tors, such as pocket proteins and histone deacetylases, may be
required. This would be consistent with an earlier report im-
plicating pocket proteins in myocyte differentiation (68). It is
also noteworthy that although both the E2F1409 mutant and
E2Fd/n lack the trans-activation domain and pocket protein
binding domain, only the E2Fd/n is able to superinduce/dere-
press differentiation marker activity. This suggests that there
may be an additional “repressor” domain between amino acid
235 and 409 of E2F1 involved in differentiation suppression.
Furthermore, the absence of an E2F consensus sequence in the
TG-1 promoter (69) would imply that an indirect mechanism
may be involved. Thus, our data are consistent with a model in
which E2Fs alter the transcription of genes that in turn regu-
late squamous differentiation.
Previous data indicate that E2F contributes causally to SCC
formation. For example, keratinocyte growth arrest and differ-
entiation are characterized by decreased E2F DNA binding
activity and E2F1 mRNA expression (3). This decrease in ex-
pression and activity does not occur in growth inhibitor-insen-
sitive SCC cell lines (3) and finally, deregulation of E2F con-
tributes to SCC formation in transgenic mice (40). Combined
with the present study, we can propose a model of squamous
neoplasia in which E2F deregulation promotes aberrant prolif-
eration and differentiation suppression in keratinocytes. It is
these two properties that present E2F as a unique target for
SCC therapy. For instance, E2F inhibition would serve the
dual purpose of inhibiting E2F-induced aberrant proliferation
of cancer cells and render these cells permissive to entering a
differentiation program in the presence of an appropriate dif-
ferentiating stimulus. Therefore, these data suggest that the
inhibition of E2F in SCC cells may provide the foundation for a
differentiation therapy. In this regard anti-E2F therapies are
already in trial in non-neoplastic proliferative disorders (44).
Our data suggest that it may be timely to extend these trials to
neoplastic disease such as SCCs.
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